Kim jesteśmy


Badania kliniczne w Polsce

Badacze z CM UMK z Katedry Kardiologii i Chorób Wewnętrznych pod kierownictwem Profesorów Jacka Kubicy i Eliano Navarese rozpoczynają unikatowy projekt badawczy, oceniający wpływ 2 ogólnodostępnych leków kardiologicznych na przebieg infekcji koronawirusem SARS-CoV-2.

Jako CLINSCIENCE dumnie wspieramy zespół badawczy w procesach prowadzących do uruchomienia badania, zgodnie z naszą misją pomagania naszym partnerom w rozwoju i prowadzeniu badań klinicznych, wspierających wprowadzenie nowych produktów, które polepszają jakość i długość życia pacjentów.

On November 14th our Operational Director Przemysław Magielski was a speaker at the „Od pomysłu do Startupu” (EN: “From idea to Startup”) conference, organized by The Cardinal Wyszynski Institute of Cardiology in Warsaw. More info (Polish) at:

On December 4th, Beata Maciejewska our Clinical Research Director attended the “Biological drugs – legal aspects” conference (PL: Leki biologiczne – aspekty prawne), which took place at the Cardinal Wyszyński University in Warsaw. For more info (in Polish), please visit:

Our Bioscience SA team is proud to announce that we are conducting a clinical trial of influenza biosensor developed by SensDx, which aims to prove the efficacy of test. Other SensDx’s biosensors, made specially for hospital-acquired infections and urology indications are planned to enter clinical trials this year.

Contact Bioscience’s team members to get more info on our solutions!

Biotechnological Company Moleculin Biotech, Inc. Begins Clinical Testing Site Development Efforts in Poland; Selects Bioscience SA as Polish CRO.

Moleculin Biotech, Inc. is a preclinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at the MD Anderson Cancer Center.
„Engaging Bioscience gives us experienced boots on the ground in Poland,” commented Walter Klemp, CEO of Moleculin, „which we believe is critical, not only for ensuring tight coordination between the US and Polish sites in our upcoming Annamycin clinical trial (which would commence only if our IND for Annamycin is permitted), but also to ensure we have the full benefit of local knowledge regarding site performance and regulatory compliance.”

Mr. Klemp continued: „one of the biggest challenges for most clinical trials is recruiting the right patients on a timely basis. We believe adding Polish sites to our planned trial introduces a significant population of qualified patients, and selecting Bioscience helps ensure we reach those patients effectively and efficiently.”

More about Moleculin: